Rinvoq (upadacitinib) / AbbVie - LARVOL DELTA

Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes (ASH 2025) - "PRO indicated substantial impairment, with 48% reporting moderate to severelimitations on EQ-5D and a median EQ-VAS score of 60.Steroid-sparing therapies included azacytidine (AZA), JAK inhibitors, conventional immunomodulatorsand cytokine blockers (TNFα, IL-1, IL-6)...JAK inhibitors (ruxolitinib, upadacitinib,tofacitinib, baricitinib) were given in 27%; 53% were switched due to lack of efficacy after a medianduration of 4 mo...Immunomodulatorsand/or cytokine blockers were used in 36% (median 2 agents, range 1–4); 40% had at least a minor clinicalresponse, most commonly with methotrexate or anti-IL-1 agents, although all anti-IL-1 treatments wereeventually discontinued due to intolerance...Our data confirm theconsiderable heterogeneity of both disease manifestations and therapeutic responses, highlighting theneed to strengthen interdisciplinary collaboration and improve treatment standards. Even though aproportion of patients had a disease onset even before VEXAS was..."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Monoclonal Gammopathy • Musculoskeletal Pain • Myelodysplastic Syndrome • Ocular Inflammation • Rheumatology • ASXL1 • DNMT3A • IL6 • SRSF2 • TET2 • TNFA

The selective JAK1 inhibitor upadacitinib restores impaired neutrophil chemotaxis in the proplatelet formation of immune thrombocytopenia (ASH 2025) - "In vivo studies showed that upadacitinibcould rescue the impaired PPF in both patients and mice model with ITP.ConclusionsThe BM of ITP patients displayed impaired neutrophil chemotaxis regulated by type I interferon pathway.Upadacitinib restores neutrophil chemotaxis and corrected impaired PPF by inhibiting type I interferonpathway and upregulating CXCR4. It sheds light on a novel mechanism of ITP pathogenesis and providesa basis for the therapeutic potential of upadacitinib in ITP patients."

Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Rheumatoid Arthritis • Rheumatology • Thrombocytopenia • Thrombocytopenic Purpura • Ulcerative Colitis • CXCL12 • IFNA1

P098 Asthma control in patients receiving systemic therapy for atopic eczema: results from the UK Atopic eczema Systemic TherApy Register (A-STAR). (PubMed, Br J Dermatol) - "Treatments initiated at enrolment included dupilumab (n = 148), methotrexate (n = 66), Janus kinase inhibitors (abrocitinib or upadacitinib, n = 52) and ciclosporin (n = 37). We plan further, similar analyses on individual drug groups in relation to asthma control, as the number of A-STAR patients in individual drug groups increases over time, enhancing statistical power.TablePredictors of achieving good asthma control (Asthma Control Test 20-25) at week 16 in multivariable analysisVariableAdjusted odds ratio (95% confidence interval)aDrug groupJanus kinase inhibitors1 (reference)Ciclosporin3.32 (0.69-17.0)Dupilumab3.34 (1.28-9.03)*Methotrexate2.89 (0.78-11.4)Baseline asthma control test score1.31 (1.20-1.45)**P < 0.05. aAdjusted for baseline Eczema Area and Severity Index and Patient-Oriented Eczema Measure, number of prior oral systemic treatments, sex, age of atopic eczema onset, age of drug initiation and Fitzpatrick skin type."

Journal • Asthma • Atopic Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases

P101 Janus kinase inhibitors in palmoplantar pustulosis: a systematic review and meta-analysis of comorbidity burden to inform a feasibility trial's design (JAKPPPOT). (PubMed, Br J Dermatol) - "These findings have been incorporated into the design of the JAKPPPOT study, a mixed-methods, single-arm feasibility trial exploring the use of the JAK inhibitor upadacitinib in PPP (REC: 24/NE/0147; opened November 2024). Trial information materials were adapted to better reflect the potential overlap in risk factors identified by this meta-analysis, and a reduced dosing strategy was introduced for participants with relevant cardiovascular disease risk factors. The findings of this trial will better inform future treatment decision making for people with PPP."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Immunology • Myocardial Infarction • Obesity • Oncology • Psoriasis

BI24 A case of refractory pyoderma gangrenosum successfully treated with upadacitinib. (PubMed, Br J Dermatol) - "The patient also had enteropathic arthritis, initially controlled with infliximab and azathioprine...Initial treatments were unsuccessful, including wound dressings, topical and systemic corticosteroids (intravenous methylprednisolone), topical tacrolimus and antibiotics. Ciclosporin was introduced when she did not respond to escalated doses of infliximab...This case highlights the importance of collaborating with other specialties regarding alternative treatments that are not available for dermatology conditions. Further studies are needed to evaluate the efficacy of Janus kinase inhibitors in PG."

Journal • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Pyoderma Gangrenosum • Rheumatoid Arthritis • Rheumatology

P113 JAK in the box: unlocking real-world factors influencing Janus kinase inhibitor and dupilumab prescribing in atopic dermatitis. (PubMed, Br J Dermatol) - "A retrospective review was carried out of patients aged ≥ 12 years prescribed dupilumab or a JAKi (upadacitinib, abrocitinib or baricitinib) for AD in our tertiary dermatology centre between 2021 and 2024. Tralokinumab and lebrikizumab were excluded as all patients had prior dupilumab...Factors favouring dupilumab prescribing include older age, asthma status and cardiovascular risk factors. Factors favouring JAKi prescribing included speed of onset, ease of prescribing, younger age and needle phobia."

Journal • Real-world evidence • Retrospective data • Alopecia • Asthma • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pulmonary Disease • Respiratory Diseases • Thrombosis • STAT2

BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases. (PubMed, Br J Dermatol) - "For eczema, therapies such as dupilumab show limited evidence in also treating AA...For instance, baricitinib is licensed for both AD and AA, while upadacitinib is licensed for AD and is currently in phase III trials for AA. Amlitelimab, which targets the OX40 ligand pathway, is currently in phase III clinical trials for atopic dermatitis and in phase II trials for severe AA...In psoriasis, overlapping therapies include ustekinumab, approved for psoriasis and being studied for AA. As for patients with RA, tofacitinib is approved for moderate-to-severe disease and is also utilized in AA. Abatacept is a cytotoxic T lymphocyte-associated protein 4 (CTLA4) immunoglobin costimulatory modulator that attenuates the activation of T cells and is widely used in RA...The Global Registry of Alopecia areata disease Severity and treatment Safety (GRASS) UK is a prospective, multicentre, observational clinical registry designed to create harmonized datasets. These datasets aim to..."

Journal • Review • Alopecia • Atopic Dermatitis • CNS Disorders • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatoid Arthritis • Rheumatology • Vitiligo • CTLA4

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P093 Switching patients who developed arthritis and/or enthesitis on dupilumab to tralokinumab: a case series. (PubMed, Br J Dermatol) - "Patient 2 developed bilateral shoulder, left Achilles tendon and back pain 2 years into dupilumab, which resolved when he switched to abrocitinib. To our knowledge, this is the first retrospective case series to report tralokinumab-associated inflammatory arthritis. These cases suggest that patients who develop arthritis or enthesitis on dupilumab are likely to experience similar symptoms on tralokinumab, and a treatment class switch (specifically to a Janus kinase inhibitor) can be beneficial.TablePatient characteristics Patient 1Patient 2Patient 3SexFemaleMaleFemaleAge (years)557028Eczema Area and Severity Index Baseline (pretreatment)23.630.329.5 On tralokinumab (month)6.1 (6)29.6 (4)2.1 (4)Arthropathy pattern Small joints+++ Large joints++-Enthesitis/tenosynovitis+++Ultrasound+N/A+CRP/ESRNormalN/ARaisedConcurrent managementNSAIDsN/ANSAIDsDuration of tralokinumab (months)13724Musculoskeletal symptom progressionImprovingResolvedImprovingTherapy after..."

Journal • Atopic Dermatitis • Back Pain • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • CRP • IL13

BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report. (PubMed, Br J Dermatol) - "The efficacy of ritlecitinib, an oral Janus kinase 3/TEC family inhibitor, has been demonstrated in the Allegro clinical trials...The US Food and Drug Administration issued black box warnings, citing increased risks of major adverse cardiovascular events, malignancies, venous thromboembolism (VTE) and mortality based on data from tofacitinib, baricitinib and upadacitinib in rheumatoid arthritis...The patient received intravenous broad-spectrum antibiotics for sepsis of unknown origin, hydrocortisone and vasopressor support for hypotension. She was anticoagulated with dalteparin and transitioned to apixaban as per respiratory advice for unprovoked pulmonary emboli...This case highlights a probable severe adverse event associated with ritlecitinib therapy, including pulmonary emboli and infection of unidentified source, associated with new-onset atrial fibrillation and acute kidney injury in a patient without known risk factors for VTE. Ongoing pharmacovigilance is..."

Journal • Acute Kidney Injury • Alopecia • Atrial Fibrillation • Cardiovascular • Dermatology • Endocrine Disorders • Hematological Disorders • Herpes Zoster • Hypotension • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Oncology • Pain • Pneumococcal Infections • Pruritus • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Septic Shock • Varicella Zoster • Venous Thromboembolism • CRP • JAK3

BH14 Irish dermatologists' experience with Janus kinase inhibitors in alopecia areata. (PubMed, Br J Dermatol) - "Interestingly, the first JAKi option in AA was reported as baricitinib (81%)...For the second JAKi option (if the first fails), 47% of respondents chose tofacitinib, followed by upadacitinib (24%)...AA poses challenges to clinicians. While JAKis show impressive efficacy, in the absence of clear literature and global guidelines to assist clinicians managing AA with JAKis, practice varies considerably."

Journal • Alopecia • Dermatology • Immunology • Inflammation

BI29 Treatment-associated anaemia on Janus kinase inhibitors for atopic dermatitis: a case report, review of the literature and discussion of treatment. (PubMed, Br J Dermatol) - "We treated a 74-year-old woman with lifelong AD, refractory to multiple systemic treatments including ciclosporin, methotrexate, mycophenolate mofetil and dupilumab, with upadacitinib 30 mg daily...Haematology recommended initiation of darbepoetin alfa at 150 μg weekly...No articles in the dermatology, rheumatology or gastroenterology literature offer advice on managing JAK inhibitor-associated anaemia, nor did we find information on restarting JAK inhibitors after resolution of anaemia outside the haematology literature. However, JAK inhibitors can safely be restarted after resolution of anaemia, which is important information in management of this complication and providing patient care."

Journal • Review • Anemia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Monoclonal Gammopathy • Pulmonary Disease • Rheumatology • JAK1 • JAK2

BI27 Treatment of recalcitrant eczema in a patient with B-cell and natural killer cell lymphopenia of unknown cause. (PubMed, Br J Dermatol) - "He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown."

Journal • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Mycosis Fungoides • Oncology • Solid Tumor • Thymoma • Thymus Cancer • Varicella Zoster • BTK • GATA2 • IL13

P114 Efficacy and safety of oral Janus kinase, tyrosine kinase 2 and phosphodiesterase 4 inhibitors in the treatment of chronic plaque psoriasis: a network meta-analysis. (PubMed, Br J Dermatol) - "After 16-24 weeks of treatment, tofacitinib and deucravacitinib had the highest efficacy, followed by apremilast, orismilast, upadacitinib and brepocitinib. Zasocitinib, a new highly selective allosteric TYK2 inhibitor, has recently demonstrated promising efficacy in the treatment of psoriasis, with 33% of patients achieving PASI 100 (complete clearance of psoriasis lesions) after just 12 weeks of treatment. In conclusion, oral TYK2 inhibitors have shown efficacy in the treatment of chronic plaque psoriasis comparable with adalimumab, with newer agents demonstrating enhanced effectiveness and surpassing PDE-4 inhibitors in therapeutic outcomes. JAK inhibitors, particularly tofacitinib, exhibit comparable efficacy to some TYK2 and PDE-4 inhibitors."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • TYK2

O06 Association between novel systemic immunomodulatory medications and achievement of super response in patients with moderate-to-severe atopic eczema: results from the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR). (PubMed, Br J Dermatol) - "Patients in A-STAR who initiated conventional systemics (oral or subcutaneous methotrexate or ciclosporin), dupilumab or a JAK1 inhibitor (abrocitinib or upadacitinib) were included in this analysis. In conclusion, treatment with dupilumab and JAK1 inhibitors is associated with a higher proportion of patients with AE achieving super response, compared with methotrexate, despite these treatments being mainly used after failure of conventional systemic medication.TableAssociation between novel systemic immunomodulatory medications and achieving super response in patients with moderate-to-severe AE. Data are expressed as the hazard ratio (95% confidence interval) CrudeAdjustedMethotrexate1 (reference)1 (reference)Ciclosporin2.25 (0.59-8.52)2.79 (0.56-13.9)Dupilumab2.20 (1.04-4.69)3.03 (1.23-7.46)JAK1 inhibitors2.75 (1.58-8.36)5.89 (2.09-16.6)."

Journal • Observational data • Atopic Dermatitis • Dermatology • Immunology • Pruritus

Highly Sensitive and Selective Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study. (PubMed, Biomed Chromatogr) - "The validated method was successfully applied to a pharmacokinetic study of a 10 mg oral formulation of upadacitinib and atorvastatin in rats. The pharmacokinetic results confirmed the applicability of the method for the reliable and simultaneous determination of both analytes in rat plasma."

Journal • PK/PD data • Preclinical

Emerging role of Janus kinase inhibitors in ulcerative colitis management. (PubMed, World J Gastrointest Pharmacol Ther) - "Tofacitinib is the first approved JAK inhibitor for the treatment of moderate-to-severe UC...These adverse effects have stressed the development of more selective agents such as upadacitinib and filgotinib...This review also highlights future directions, including the potential of selective JAK1 inhibition and the role of personalized medicine in refining therapeutic decisions. Understanding the emerging place of JAK inhibitors within the UC treatment strategies offers excellent opportunities to increase patient care and long-term disease management."

Journal • Review • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • JAK1

Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines. (PubMed, ACR Open Rheumatol) - "All JAKi reduced EC inflammation but most JAKi could not prevent the up-regulation of adhesion molecules or the increase in procoagulant and the decrease in anticoagulant factors triggered by proinflammatory cytokines. Peficitinib and fedratinib exhibited cytotoxic effects causing EC apoptosis."

Journal • Cardiovascular • Oncology • ANXA5 • CXCL8 • ICAM1 • IL17A • IL6 • TNFA • VCAM1

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. (PubMed, Clin Transl Sci) - "This study analyzed VigiBase, the World Health Organization global pharmacovigilance database of individual case safety reports (ICSRs), to assess signals of disproportionate reporting (SDRs) for pregnancy-related adverse drug reactions (ADRs) reported with systemic JAKIs, including abrocitinib, baricitinib, deucravacitinib, fedratinib, filgotinib, itacitinib, momelotinib, pacritinib, peficitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib. Findings should be interpreted cautiously given the limitations of spontaneous reporting systems and the exploratory nature of the analysis. Further studies are needed to better characterize the JAKI safety in pregnancy."

Adverse drug reaction • Adverse events • Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Prepuberty Exposure to Polystyrene Nanoplastics Induces Cardiac Inflammation Through Calcium Overload-Mediated ROS/JAK1/STAT3 Signaling Cascade. (PubMed, Free Radic Biol Med) - "Treatment of HL-1 cells with N-Acetylcysteine (NAC) normalized the activity of the JAK1/STAT3 pathway and the levels of inflammatory cytokines. Furthermore, either inhibition of JAK1 with upadacitinib or knockdown of STAT3 in PS-NP-exposed HL-1 cells led to proinflammatory cytokine levels comparable to those in control cells...Notably, pharmacological inhibition of calcium flux attenuated PS-NP-induced mitochondrial dysfunction, oxidative stress, and inflammatory responses in HL-1 cardiomyocytes. Collectively, our findings indicate that prepubertal PS-NP exposure triggers cardiac inflammation, which is likely mediated by MAM-dependent mitochondrial calcium overload and subsequent activation of the ROS/JAK1/STAT3 signaling axis."

Journal • Inflammation • Metabolic Disorders • HSPA9 • IL17A • IL6 • JAK1 • TNFA • VDAC1

Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors. (PubMed, Intern Med) - "HZ incidence varied by JAK inhibitor: baricitinib (5.5 vs 9.9), upadacitinib (12.4 vs 6.2), and filgotinib (0.0 vs 1.6) per 100 person-years. Conclusion Although not statistically significant, RZV vaccination tended to reduce the incidence of HZ in Japanese RA patients receiving JAK inhibitors. The effectiveness varied according to the type of JAK inhibitor, with lower lymphocyte counts and higher disease activity, and it may predict insufficient protection."

Journal • Herpes Zoster • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Varicella Zoster

Beyond events per 100 patient-years: Interpreting 6-year upadacitinib safety in atopic dermatitis. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Small-molecule therapies for pediatric inflammatory bowel disease: toward precision medicine. (PubMed, World J Pediatr) - "Small-molecule therapies offer a promising and mechanistically precise direction for the management of pIBD. Future progress will depend on age-specific clinical trials, physiologically based pharmacokinetic modeling, and biomarker discovery through integrated multiomics. Collaborative multicenter research is essential to optimize the safety and efficacy of these agents in children."

Journal • Review • Cardiovascular • Developmental Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Oncology • Pediatrics

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review. (PubMed, Ann Med) - "Recent clinical case reports and early studies have shown favourable outcomes with JAK inhibitors, such as tofacitinib, upadacitinib, baricitinib, deucravacitinib and abrocitinib, in refractory PPP cases. JAK inhibitors emerge as a promising therapeutic strategy for PPP, due to their ability to block multiple inflammatory pathways simultaneously, especially where other cytokine-targeted therapies have failed. However, despite compelling early reports, larger controlled trials are essential to establish definitive efficacy, clarify long-term safety and optimize clinical use."

Journal • Review • Cardiovascular • Dermatology • Herpes Zoster • Immunology • Pain • Psoriasis • Varicella Zoster

Interleukin-6 Inhibitor-Induced Leukocytoclastic Vasculitis: A Case Report With a Literature Review. (PubMed, Case Reports Immunol) - "Her rheumatoid arthritis had been managed with upadacitinib for several years, which was discontinued due to persistent transaminitis...The rash resolved slowly in a month after discontinuation of tocilizumab and prescription of prednisone 20 mg daily. At her 3-month follow-up, the patient remained in remission, and her rheumatoid arthritis was uneventfully managed with abatacept. While most cases of biologic-associated LCV are induced by TNF-α inhibitors, only two known cases of tocilizumab-induced hypersensitivity vasculitis have been published in the literature. Our case represents only the third reported instance in the literature, highlighting the need to raise awareness of tocilizumab as a potential cause of leukocytoclastic vasculitis and the importance of prompt recognition and management."

Journal • Fatigue • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Vasculitis • ERBB3 • IL6